Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
This was a phase II multi-center, randomized, open-label study with two parallel study groups
to evaluate the efficacy and safety of PG2 in ITP patients.